Active surveillance (AS) in prostate cancer (PCa) represents a curative alternative for men with localised low-risk PCa. Continuous improvement of AS patient's selection and surveillance modalities aims at reducing misclassification, simplifying modalities of surveillance and decreasing need for invasive procedures such repeated biopsies. Biomarkers represent interesting tools to evaluate PCa diagnosis and prognosis, of which many are readily available or under evaluation. The aim of this review is to investigate the biomarker performance for AS selection and patient outcome prediction. Blood, urinary and tissue biomarkers were studied and a brief description of use was proposed along with a summary of major findings. Biomarkers represent promising tools which could be part of a more tailored risk AS strategy aiming to offer personalized medicine and to individualize the treatment and monitoring of each patient. The usefulness of biomarkers has mainly been suggested for AS selection, whereas few studies have investigated their role during the monitoring phase. Randomized prospective studies dealing with imaging are needed as well as larger prospective studies with long-term follow-up and strong oncologic endpoints.
Cancers. 2021 Aug 24*** epublish ***
Cécile Manceau, Gaëlle Fromont, Jean-Baptiste Beauval, Eric Barret, Laurent Brureau, Gilles Créhange, Charles Dariane, Gaëlle Fiard, Mathieu Gauthé, Romain Mathieu, Raphaële Renard-Penna, Guilhem Roubaud, Alain Ruffion, Paul Sargos, Morgan Rouprêt, Guillaume Ploussard
Department of Urology, CHU-IUC Toulouse, F-31000 Toulouse, France., Department of Pathology, CHRU Tours, F-37000 Tours, France., Department of Urology, La Croix du Sud Hospital, F-31130 Quint Fonsegrives, France., Department of Urology, Institut Mutualiste Montsouris, F-75014 Paris, France., Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, F-97110 Pointe-à-Pitre, France., Department of Radiation Oncology, Curie Institute, F-75005 Paris, France., Department of Urology, Hôpital Européen Georges-Pompidou, APHP, Paris-Paris University-U1151 Inserm-INEM, Necker, F-75015 Paris, France., Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, F-38000 Grenoble, France., AP-HP Health Economics Research Unit, INSERM-UMR1153, F-75004 Paris, France., Department of Urology, CHU Rennes, F-35033 Rennes, France., Department of Radiology, Sorbonne University, AP-HP, Pitie-Salpetriere Hospital, F-75013 Paris, France., Department of Medical Oncology, Institut Bergonié, F-33000 Bordeaux, France., Service d'Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69002 Lyon, France., Department of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France., Department of Urology, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, F-75013 Paris, France.